TrialRheumatology (Oxford, England)2025

Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.

Andreu Fernández-Codina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.